Trials / Completed
CompletedNCT01879917
Liraglutide in Newly Onset Type 1 Diabetes.
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Trial of Liraglutide Treatment in Subjects With Newly Diagnosed Type 1 Diabetes.
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Hvidovre University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liraglutide | |
| DRUG | Placebo | Saline |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2013-06-18
- Last updated
- 2021-03-30
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01879917. Inclusion in this directory is not an endorsement.